353 related articles for article (PubMed ID: 16269974)
1. Hemodynamic and metabolic responses to valsartan and atenolol in obese hypertensive patients.
Jordan J; Engeli S; Boschmann M; Weidinger G; Luft FC; Sharma AM; Kreuzberg U
J Hypertens; 2005 Dec; 23(12):2313-8. PubMed ID: 16269974
[TBL] [Abstract][Full Text] [Related]
2. Angiotensin type 2 receptor in resistance arteries of type 2 diabetic hypertensive patients.
Savoia C; Touyz RM; Volpe M; Schiffrin EL
Hypertension; 2007 Feb; 49(2):341-6. PubMed ID: 17159079
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.
Ruilope LM; Malacco E; Khder Y; Kandra A; Bönner G; Heintz D
Clin Ther; 2005 May; 27(5):578-87. PubMed ID: 15978306
[TBL] [Abstract][Full Text] [Related]
4. Angiotensin receptor blocker added to previous antihypertensive agents on arteries of diabetic hypertensive patients.
Savoia C; Touyz RM; Endemann DH; Pu Q; Ko EA; De Ciuceis C; Schiffrin EL
Hypertension; 2006 Aug; 48(2):271-7. PubMed ID: 16785331
[TBL] [Abstract][Full Text] [Related]
5. Combination therapy versus monotherapy as initial treatment for stage 2 hypertension: a prespecified subgroup analysis of a community-based, randomized, open-label trial.
Everett BM; Glynn RJ; Danielson E; Ridker PM;
Clin Ther; 2008 Apr; 30(4):661-72. PubMed ID: 18498915
[TBL] [Abstract][Full Text] [Related]
6. AT1-receptor blockade improves augmentation index: a double-blind, randomized, controlled study.
Klingbeil AU; John S; Schneider MP; Jacobi J; Weidinger G; Schmieder RE
J Hypertens; 2002 Dec; 20(12):2423-8. PubMed ID: 12473867
[TBL] [Abstract][Full Text] [Related]
7. Combination of hydrochlorothiazide or benazepril with valsartan in hypertensive patients unresponsive to valsartan alone.
Waeber B; Aschwanden R; Sadecky L; Ferber P
J Hypertens; 2001 Nov; 19(11):2097-104. PubMed ID: 11677377
[TBL] [Abstract][Full Text] [Related]
8. Effect of crossing over hypertensive patients from a beta-blocker to an angiotensin receptor antagonist on resistance artery structure and on endothelial function.
Schiffrin EL; Park JB; Pu Q
J Hypertens; 2002 Jan; 20(1):71-8. PubMed ID: 11791028
[TBL] [Abstract][Full Text] [Related]
9. Angiotensin receptor blocker/diuretic combination preserves insulin responses in obese hypertensives.
Sowers JR; Raij L; Jialal I; Egan BM; Ofili EO; Samuel R; Zappe DH; Purkayastha D; Deedwania PC
J Hypertens; 2010 Aug; 28(8):1761-9. PubMed ID: 20498618
[TBL] [Abstract][Full Text] [Related]
10. Effect of valsartan and atenolol on sexual behavior in hypertensive postmenopausal women.
Fogari R; Preti P; Zoppi A; Corradi L; Pasotti C; Rinaldi A; Mugellini A
Am J Hypertens; 2004 Jan; 17(1):77-81. PubMed ID: 14700518
[TBL] [Abstract][Full Text] [Related]
11. Real-world effectiveness of amlodipine/valsartan and amlodipine/valsartan/hydrochlorothiazide in high-risk patients and other subgroups.
Assaad-Khalil SH; Najem R; Sison J; Kitchlew AR; Cho B; Ueng KC; DiTommaso S; Shete A
Vasc Health Risk Manag; 2015; 11():71-8. PubMed ID: 25653536
[TBL] [Abstract][Full Text] [Related]
12. [Lowering of blood pressure, blood pressure amplitude and heart rate by treatment with valsartan or valsartan/hydrochlorothiazide. Results of an open observation study of 11,447 hypertensives].
Weisser B; Vetter H; Mengden T
Dtsch Med Wochenschr; 2003 Mar; 128(11):541-4. PubMed ID: 12635025
[TBL] [Abstract][Full Text] [Related]
13. Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension.
Thürmann PA; Kenedi P; Schmidt A; Harder S; Rietbrock N
Circulation; 1998 Nov; 98(19):2037-42. PubMed ID: 9808602
[TBL] [Abstract][Full Text] [Related]
14. Antihypertensive efficacy and tolerability of two fixed-dose combinations of valsartan and hydrochlorothiazide compared with valsartan monotherapy in patients with stage 2 or 3 systolic hypertension: an 8-week, randomized, double-blind, parallel-group trial.
Lacourcière Y; Poirier L; Hebert D; Assouline L; Stolt P; Rehel B; Khder Y
Clin Ther; 2005 Jul; 27(7):1013-21. PubMed ID: 16154480
[TBL] [Abstract][Full Text] [Related]
15. Valsartan/hydrochlorothiazide is effective in hypertensive patients inadequately controlled by valsartan monotherapy.
Mallion JM; Carretta R; Trenkwalder P; Martinez JF; Tykarski A; Teitelbaum I; Oddou P; Fagan T;
Blood Press Suppl; 2003 May; 1():36-43. PubMed ID: 12800986
[TBL] [Abstract][Full Text] [Related]
16. Effect on blood pressure control of switching from valsartan monotherapy to losartan/hydrochlorothiazide in Asian patients with hypertension: results of a multicentre open-label trial.
Watanabe LA; Wei M; Sun N; Kim D; Chiang CE; Ke Y; Tseng CD; Coloma R; Vala M; Massaad R; Feig P; Guptha S
Curr Med Res Opin; 2006 Oct; 22(10):1955-64. PubMed ID: 17022855
[TBL] [Abstract][Full Text] [Related]
17. Effect of bunazosin and atenolol on glucose metabolism in obese, nondiabetic patients with primary hypertension.
Bönner G; Schmieder R; Chrosch R; Weidinger G
Cardiovasc Drugs Ther; 1997 Mar; 11(1):21-6. PubMed ID: 9140673
[TBL] [Abstract][Full Text] [Related]
18. Retinal dysfunction in diabetic ren-2 rats is ameliorated by treatment with valsartan but not atenolol.
Phipps JA; Wilkinson-Berka JL; Fletcher EL
Invest Ophthalmol Vis Sci; 2007 Feb; 48(2):927-34. PubMed ID: 17251496
[TBL] [Abstract][Full Text] [Related]
19. An ambulatory blood pressure monitoring study of the comparative antihypertensive efficacy of two angiotensin II receptor antagonists, irbesartan and valsartan.
Mancia G; Korlipara K; van Rossum P; Villa G; Silvert B
Blood Press Monit; 2002 Apr; 7(2):135-42. PubMed ID: 12048432
[TBL] [Abstract][Full Text] [Related]
20. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial.
Julius S; Kjeldsen SE; Weber M; Brunner HR; Ekman S; Hansson L; Hua T; Laragh J; McInnes GT; Mitchell L; Plat F; Schork A; Smith B; Zanchetti A;
Lancet; 2004 Jun; 363(9426):2022-31. PubMed ID: 15207952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
